US Global Jets ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? US Global Jets ETF trades at $27.18 (market cap $878.48M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.47 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 2.6× US Global Jets ETF's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| JETS | SLS | |
|---|---|---|
Market Cap | $878.48M | $2.27B |
Volume | 4,465,925 | 4,179,659 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $15.46 |
52-Week Low | $23.64 | $1.39 |
Typical Hold Time | 26 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.
No Aura AI signal available yet.
Trailing returns across standard periods
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →